Page 64 - 南京医科大学学报自然科学版
P. 64
第43卷第12期
·1680 · 南 京 医 科 大 学 学 报 2023年12月
ne for human epidermal growth factor receptor 2⁃positive Engl J Med,2012,367(19):1783-1791
metastatic breast cancer after trastuzumab and taxanes [15] BARTSCH R,BERGHOFF A S,FURTNER J,et al.
(PHENIX):a randomized,double ⁃ blind,placebo ⁃ con⁃ Trastuzumab deruxtecan in HER2⁃positive breast cancer
trolled phase 3 study[J]. Transl Breast Cancer Res, with brain metastases:a single⁃arm,phase 2 trial[J]. Nat
2020,1:13 Med,2022,28(9):1840-1847
[9] XU B,YAN M,MA F,et al. Pyrotinib plus capecitabine [16] COLLINS D M,MADDEN S F,GAYNOR N,et al. Effects
versus lapatinib plus capecitabine for the treatment of of HER family⁃targeting tyrosine kinase inhibitors on anti⁃
HER2 ⁃ positive metastatic breast cancer(PHOEBE):a body⁃dependent cell⁃mediated cytotoxicity in HER2⁃ex⁃
multicentre,open⁃label,randomised,controlled,phase 3 pressing breast cancer[J]. Clin Cancer Res,2021,27
trial[J]. Lancet Oncol,2021,22(3):351-360 (3):807-818
[10] 王晓闻,刘培培,吕锋华,等. 抗HER2人源化单克隆抗 [17] WANG T,ZHANG P,DI L,et al. Efficacy and safety of in⁃
体药物关键质量属性评价[J]. 中国药学杂志,2015,50 etetamab in combination with chemotherapy as first⁃line
(12):1054-1061 treatment of HER2 ⁃ positive metastatic breast cancer:a
[11] 边 莉,徐兵河,邸立军,等. 重组抗HER2人源化单克 subgroup analysis in the HOPES study[J/OL]. Transl
隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随 Breast Cancer Res,2022,3:15
机对照Ⅲ期临床研究[J]. 中华医学杂志,2020,100 [18] RUGO H S,IM S A,CARDOSO F,et al. Efficacy of mar⁃
(30):2351-2357 getuximab vs trastuzumab in patients with pretreated
[12] GOLDHIRSCH A,WOOD W C,COATES A S,et al. Strat⁃ ERBB2⁃positive advanced breast cancer:a phase 3 ran⁃
egies for subtypes—dealing with the diversity of breast domized clinical trial[J]. JAMA Oncol,2021,7(4):573
cancer:highlights of the St Gallen International Expert [19] VIVEKANANDHAN S,KNUTSON K L. Resistance to
Consensus on the Primary Therapy of Early Breast Cancer trastuzumab[J]. Cancers,2022,14(20):5115
2011[J]. Ann Oncol,2011,22(8):1736-1747 [20] LU Y,ZI X,POLLAK M. Molecular mechanisms underly⁃
[13] XU B,LI W,ZHANG Q,et al. Pertuzumab,trastuzumab, ing IGF⁃I⁃induced attenuation of the growth⁃inhibitory ac⁃
and docetaxel for Chinese patients with previously un⁃ tivity of trastuzumab(Herceptin)on SKBR3 breast cancer
treated HER2 ⁃ positive locally recurrent or metastatic cells[J]. Int J Cancer,2004,108(3):334-341
breast cancer(PUFFIN):a phase III,randomized,double⁃ [21] MURTHY R K,LOI S,OKINES A,et al. Tucatinib,trastu⁃
blind,placebo ⁃ controlled study[J]. Breast Cancer Res zumab,and capecitabine for HER2 ⁃ positive metastatic
Treat,2020,182(3):689-697 breast cancer[J]. N Engl JMed,2020,382(7):597-609
[14] VERMA S,MILES D,GIANNI L,et al. Trastuzumab em⁃ [收稿日期] 2023-06-19
tansine for HER2⁃positive advanced breast cancer[J]. N (本文编辑:唐 震)
(上接第1655页) 1425
[22] KAPLAN L,CHOW B W,GU C. Neuronal regulation of [25]王红霞,孟国梁,谢佳彤,等. 硫化氢对异丙肾上腺素诱
the blood ⁃ brain barrier and neurovascular coupling[J]. 导小鼠急性心肌损伤的保护作用及机制研究[J]. 南京
Nat Rev Neurosci,2020,21(8):416-432 医科大学学报(自然科学版),2018,38(3):305-309
[23] PINTEAC R,MONTALBAN X,COMABELLA M. Chitin⁃ [26] 朱海燕,赵晓晶,宋晶晶,等. 紫草素通过抑制氧化应激
ases and chitinase⁃like proteins as biomarkers in neuro⁃ 和神经炎症在脑外伤后发挥神经保护作用[J]. 南京医
logic disorders[J]. Neurol Neuroimmunol Neuroinflamm, 科大学学报(自然科学版),2022,42(8):1055-1064
2021,8(1):e921 [27] PAUL B D,SNYDER S H,KASHFI K. Effects of hydro⁃
[24]张雅旋,郭瑞娟,张 寅,等. 外周血S100钙结合蛋白、 gen sulfide on mitochondrial function and cellular bioen⁃
Hcy及神经元特异性烯醇化酶水平与创伤性颅脑损伤患 ergetics[J]. Redox Biol,2021,38:101772
者颅内血肿吸收情况及认知功能的相关性分析[J]. 南 [收稿日期] 2023-07-29
京医科大学学报(自然科学版),2022,42(10):1421- (本文编辑:唐 震)